GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

This study evaluates the association between GLP-1 receptor agonists and ischemic optic neuropathy risk compared to SGLT2 and DPP-4 inhibitors, revealing a small but statistically significant increased risk with GLP-1RAs, particularly among older men with cardiovascular or eye conditions.
Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension: Evidence, Mechanisms, and Clinical Implications

Nicotinamide Supplementation and Primary Open-Angle Glaucoma in Patients With Ocular Hypertension: Evidence, Mechanisms, and Clinical Implications

Systemic nicotinamide supplementation is associated with reduced risk of POAG development in ocular hypertension, improved retinal function, and better quality of life, suggesting its neuroprotective potential as an adjunctive therapy in glaucoma prevention and management.